WO2001072341A3 - Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie - Google Patents

Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie Download PDF

Info

Publication number
WO2001072341A3
WO2001072341A3 PCT/US2001/009042 US0109042W WO0172341A3 WO 2001072341 A3 WO2001072341 A3 WO 2001072341A3 US 0109042 W US0109042 W US 0109042W WO 0172341 A3 WO0172341 A3 WO 0172341A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapy
combinations
target cell
radiation
methods
Prior art date
Application number
PCT/US2001/009042
Other languages
English (en)
Other versions
WO2001072341A2 (fr
Inventor
De-Chao Yu
Yu Chen
Daniel R Henderson
Original Assignee
Cell Genesys Inc
De-Chao Yu
Yu Chen
Daniel R Henderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, De-Chao Yu, Yu Chen, Daniel R Henderson filed Critical Cell Genesys Inc
Priority to AU2001243704A priority Critical patent/AU2001243704B2/en
Priority to JP2001570302A priority patent/JP2003532638A/ja
Priority to CA002404060A priority patent/CA2404060A1/fr
Priority to EP01916717A priority patent/EP1318839A2/fr
Priority to AU4370401A priority patent/AU4370401A/xx
Publication of WO2001072341A2 publication Critical patent/WO2001072341A2/fr
Publication of WO2001072341A3 publication Critical patent/WO2001072341A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des méthodes de traitement de la néoplasie avec des vecteurs adénoviraux spécifiques des cellules cibles capables de réplication, associés à la chimiothérapie ou à la radiothérapie, ou leurs combinaisons. Les vecteurs adénoviraux sont spécifiques des cellules cibles pour le type particulier de néoplasie pour lequel le traitement est nécessaire, et la chimiothérapie et/ou la radiothérapie combinées fournissent un traitement synergique relativement aux thérapies adénovirales existantes ou aux chimiothérapies et radiothérapies classiques.
PCT/US2001/009042 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie WO2001072341A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001243704A AU2001243704B2 (en) 2000-03-24 2001-03-21 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
JP2001570302A JP2003532638A (ja) 2000-03-24 2001-03-21 標的細胞特異的アデノウイルス、化学療法および放射線療法の組み合わせによる新生物の治療法
CA002404060A CA2404060A1 (fr) 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
EP01916717A EP1318839A2 (fr) 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
AU4370401A AU4370401A (en) 2000-03-24 2001-03-21 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19201500P 2000-03-24 2000-03-24
US60/192,015 2000-03-24

Publications (2)

Publication Number Publication Date
WO2001072341A2 WO2001072341A2 (fr) 2001-10-04
WO2001072341A3 true WO2001072341A3 (fr) 2003-03-20

Family

ID=22707882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009042 WO2001072341A2 (fr) 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie

Country Status (5)

Country Link
EP (1) EP1318839A2 (fr)
JP (1) JP2003532638A (fr)
AU (2) AU2001243704B2 (fr)
CA (1) CA2404060A1 (fr)
WO (1) WO2001072341A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511203A (ja) * 2000-03-24 2004-04-15 セル　ジェネシス　インコーポレーティッド 内部リボソーム接近部位を含む細胞特異的なアデノウイルスベクター
CA2439185A1 (fr) 2001-02-23 2002-09-06 Novartis Ag Nouvelles constructions de vecteurs
US7371570B2 (en) 2002-11-01 2008-05-13 Cell Genesys, Inc. Cell-specific adenovirus vector comprising EBV-specific promoter
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
EP1900749A1 (fr) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Acide nucléique pour l'expression d'un polynucléotide d'interêt dans des cellules cancéreuses de mammiferès
CN104812446B (zh) * 2012-10-24 2020-04-14 密歇根大学董事会 癌干细胞接种和治疗
CN112980884A (zh) * 2021-03-03 2021-06-18 北京中因科技有限公司 一种提高腺相关病毒感染细胞感染效率的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010007A1 (fr) * 1995-09-13 1997-03-20 Genetic Therapy, Inc. Traitement du cancer
WO1998039467A2 (fr) * 1997-03-03 1998-09-11 Calydon, Inc. Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
WO1998039464A2 (fr) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
WO1999025860A1 (fr) * 1997-11-19 1999-05-27 Novartis Ag Vecteur pour replication et expression genique a specificite tissulaire
WO1999059604A1 (fr) * 1998-05-15 1999-11-25 Onyx Pharmaceuticals, Inc. Combinaison d'adenovirus et de chimiotherapiepour le traitement du cancer
WO2000015820A1 (fr) * 1998-09-10 2000-03-23 Calydon, Inc. Vecteurs d'adenovirus contenant des elements de reponse specifiques de l'etat des cellules, et procedes d'utilisation desdits vecteurs
WO2000039319A2 (fr) * 1998-12-30 2000-07-06 Calydon, Inc. Vecteurs adenoviraux specifiques de cellules cibles renfermant la sequence e3 et leurs methodes d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010007A1 (fr) * 1995-09-13 1997-03-20 Genetic Therapy, Inc. Traitement du cancer
WO1998039467A2 (fr) * 1997-03-03 1998-09-11 Calydon, Inc. Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
WO1998039464A2 (fr) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
WO1999025860A1 (fr) * 1997-11-19 1999-05-27 Novartis Ag Vecteur pour replication et expression genique a specificite tissulaire
WO1999059604A1 (fr) * 1998-05-15 1999-11-25 Onyx Pharmaceuticals, Inc. Combinaison d'adenovirus et de chimiotherapiepour le traitement du cancer
WO2000015820A1 (fr) * 1998-09-10 2000-03-23 Calydon, Inc. Vecteurs d'adenovirus contenant des elements de reponse specifiques de l'etat des cellules, et procedes d'utilisation desdits vecteurs
WO2000039319A2 (fr) * 1998-12-30 2000-07-06 Calydon, Inc. Vecteurs adenoviraux specifiques de cellules cibles renfermant la sequence e3 et leurs methodes d'utilisation

Also Published As

Publication number Publication date
AU4370401A (en) 2001-10-08
CA2404060A1 (fr) 2001-10-04
WO2001072341A2 (fr) 2001-10-04
JP2003532638A (ja) 2003-11-05
AU2001243704B2 (en) 2005-10-27
EP1318839A2 (fr) 2003-06-18

Similar Documents

Publication Publication Date Title
WO2005107474A3 (fr) Adenovirus oncolytique a genes therapeutiques
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
AP2004002995A0 (en) Combination therapy for the treatment of cancer
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
BRPI0213223B8 (pt) polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
WO2001023405A3 (fr) Traitement therapeutique d'affections causees par le recepteur androgene
WO2002042468A3 (fr) Vecteurs de glycosyltransferase pour traitement du cancer
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
EP1652931A3 (fr) Adénovirus recombinants, préparation et utilisation pour le traitement et/ou la prévention des cancers
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002074237A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
PT1300084E (pt) Composicaio para o tratamento de insuficiencias venosas cronicas melha.
WO2001072341A3 (fr) Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
IL125776A (en) Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors
BRPI0415896A (pt) combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
WO2003037267A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
DK1107795T3 (da) Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis
WO2004029287A3 (fr) Polypeptides et acides nucleiques codant ceux-ci et utilisation de ceux-ci pour la prevention, le diagnostic ou le traitement de troubles du foie et du cancer epithelial
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
WO2001094409A3 (fr) Traitement et diagnostic du cancer du pancreas et compositions a cet effet
WO2001034548A3 (fr) Substitution par heteroatome en position 3 et deux homologues carbones de 15-hete et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2404060

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 570302

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001243704

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001916717

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001916717

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001243704

Country of ref document: AU